Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Genenta Science SpA Sponsored ADR ( (GNTA) ) has issued an update.
On May 18, 2026, Genenta Science’s board approved terminating its amended and restated license agreement with Ospedale San Raffaele, which covered certain technologies and intellectual property rights. The company said the move followed a strategic review and is not expected to trigger any material termination fees beyond already accrued obligations.
The decision allows Genenta to redirect resources toward its ongoing business and strategic initiatives, signaling a refocus of its development priorities. Genenta will continue to support and monitor its active glioblastoma multiforme clinical trial, where two patients remain under observation, suggesting its core oncology program will proceed despite the licensing exit.
The most recent analyst rating on (GNTA) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Genenta Science SpA Sponsored ADR stock, see the GNTA Stock Forecast page.
More about Genenta Science SpA Sponsored ADR
Genenta Science S.p.A. is a Milan-based biotechnology company focused on developing gene- and cell-based therapies, including treatments targeting aggressive cancers such as glioblastoma multiforme. The company’s research-driven model centers on leveraging advanced genetic engineering technologies to address high unmet medical needs in oncology.
Average Trading Volume: 75,054
Technical Sentiment Signal: Sell
Current Market Cap: $14.72M
See more data about GNTA stock on TipRanks’ Stock Analysis page.